AstraZeneca (AZ) has reported full-year 2025 revenue of USD 58.7 billion, an 8% year-on-year increase, with product sales rising 10% to USD 58.6 billion. R&D investment grew 4% to USD 14.2 billion. The company's oncology franchise remained its largest business unit, contributing USD 25.6 billion, a 14% increase that accounted for 44% of total product revenue. Growth was driven by key assets including Enhertu (trastuzumab deruxtecan), which generated USD 5.0 billion in sales, and Datroway (datopotamab deruxtecan). The company ended the year with 15 blockbuster products.

Geographically, AZ's revenue in China grew 4% to USD 6.7 billion, maintaining its position as the top multinational pharmaceutical company in the Chinese market for the second consecutive year. The US market generated USD 25.4 billion, a 10% increase. The company is forecasting mid-to-high single-digit revenue growth for 2026, supported by a pipeline of upcoming regulatory decisions and Phase III data readouts across its oncology, cardiovascular, renal, metabolism, respiratory, immunology, and rare disease portfolios.

PharmCube's NextBiopharm® database shows that the company's global pipeline includes 37 late-stage candidates and 4 undergoing regulatory review. Click here to request a free trial for NextBiopharm®.